Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium

Next Previous
Trial Profile

A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Odanacatib (Primary) ; Calcium; Colecalciferol
  • Indications Fracture; Postmenopausal osteoporosis
  • Focus Biomarker; Registrational; Therapeutic Use
  • Acronyms LOFT
  • Sponsors Merck Sharp & Dohme

Most Recent Events

  • 01 Oct 2022 Results of post-hoc analysis assessing odanacatib mechanism of action on bone-turnover biomarkers, published in the Osteoporosis International.
  • 06 Apr 2022 This trial has been completed in Norway (End Date: 03 Apr 2009), according to European Clinical Trials Database record (EudraCT2009-011920-69).
  • 06 Apr 2022 This trial has been completed in Norway (End Date: 03 Apr 2009), according to European Clinical Trials Database record (EudraCT2009-011920-69).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top